Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5116965 | 0.94 | F2 (0.53) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5754173 | 0.93 | F2 (0.51) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5754215 | 0.91 | F2 (0.56) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5755807 | 0.90 | F2 (0.56) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5755992 | 0.90 | F2 (0.62) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5756725 | 0.90 | F2 (0.54) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5753975 | 0.90 | F2 (0.57) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL14145037 | 0.90 | F2 (0.56) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5756043 | 0.90 | F2 (0.54) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5755919 | 0.89 | F2 (0.54) | F2PRSS1PRSS2PRSS3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | claimed |
| US-7029654-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| US-20040106633-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | claimed |
| US-6706021-B2 | ANTICOAGULANT FOR CATHETERS, DIALYSIS MACHINES, SYRINGES, TUBES, BLOOD LINES AND STENTS; TRYPSIN-LIKE SERINE PROTEASES SUCH AS THROMBIN; 3-BENZYLSULFONYLAMINO-6-METHYL-1-((2-GUANIDINOOXYETHYL) AMINOCARBONYLMETHYL)-2-PYRIDINONE | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | claimed |
| US-6350764-B2 | FOR INHIBITING LOSS OF BLOOD PLATELETS; INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, FIBRIN, THROMBUS, AND EMBOLUS; ANTICOAGULANTS EMBEDDED IN DEVICES FOR BLOOD COLLECTION, CIRCULATION, STORAGE (CATHETERS, DIALYSIS MACHINES); STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-26 | — | — | US | claimed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1611094-A1 | PYRAZOLE COMPOUNDS | MERCK PATENT GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089888-A1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106633-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | F2 27/4885PRSS1 32/4885PRSS2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.